IUPAC/Chemical Name
4,4'-methylenebis(1,2,4-thiadiazinane 1,1-dioxide)
InChi Key
AJKIRUJIDFJUKJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C7H16N4O4S2/c12-16(13)3-1-10(5-8-16)7-11-2-4-17(14,15)9-6-11/h8-9H,1-7H2
SMILES Code
O=S1(CCN(CN2CNS(CC2)(=O)=O)CN1)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
284.35
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1. Calabresi, P., Goulette, F.A., and Darnowski, J.W. Taurolidine: Cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Research 61(18), 6816-6821 (2001).
2. Caruso, F., Darnowski, J.W., Opazo, C., et al. Taurolidine antiadhesive properties on interaction with E. coli; its transformation in biological environment and interaction with bacteria cell wall. PLoS One 5(1), e8927 (2010).
3. Watson, R.W., Redmond, H.P., McCarthy, J., et al. Taurolidine, an antilipopolysaccharide agent, has immunoregulatory properties that are mediated by the amino acid taurine. Journal of Leukocyte Biology 58(3), 299-306 (1995).
4. Chromik, A.M., Daigeler, A., Bulut, D., et al. Comparative analysis of cell death induction by taurolidine in different malignant human cancer cell lines. J.Exp.Clin.Cancer Res. 29, 21 (2010).
5. Stendel, R., Biefer, H.R., Dékány, G.M., et al. The antibacterial substance taurolidine exhibits anti-neoplastic action based on a mixed type of programmed cell death. Autophagy 5(2), 194-210 (2009).
6. Aceto, N., Bertino, P., Barbone, D., et al. Taurolidine and oxidative stress: A rationale for local treatment of mesothelioma. European Respiratory Journal 34(6), 1399-1407 (2009).
